The "Adeno-Associated Virus (AAV) Vectors in Gene Therapy – Market Insight, Epidemiology and Market Forecast – 2030" drug pipelines has been added to ResearchAndMarkets.com’s offering. This report ...

In a recent review published in Signal Transduction and Targeted Therapy, researchers presented recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases. Study: ...

The "Adeno-Associated Virus (AAV) Vectors in Gene Therapy – Epidemiology Insight – 2030" report has been added to ResearchAndMarkets.com’s offering. This ‘Adeno-Associated Virus (AAV) Vector Based ...

Dyno Therapeutics unveils best-in-class Dyno-bn8 AAV vector for muscle gene therapies, achieving therapeutic delivery with improved safety potential ...

Journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. Recent clinical trials utilizing high doses of adeno ...

This report, published by Towards Healthcare, a sister firm of Precedence Research, provides an in-depth analysis of the ...

REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related ...

Andelyn Biosciences has entered a non-exclusive worldwide license and collaboration agreement with Solid Biosciences Inc. for ...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced results of a well ...

AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.